CDTX:US
$61.85
-1.544%
Cidara Therapeutics Inc.News & Events
Last updated: Jul 28, 2025, 3:06 AM ET
Cidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025
GlobeNewswire JUL 24, 2025 8:00 AM EDTSAN DIEGO, July 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechn...READ ARTICLECidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewswire JUL 1, 2025 4:59 PM EDTSAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechn...READ ARTICLECidara Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
GlobeNewswire JUN 30, 2025 8:00 AM EDTSAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechn...READ ARTICLECidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewswire JUN 26, 2025 5:15 PM EDTSAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (...READ ARTICLECidara Announces Pricing of Upsized Public Offering of Common Stock
GlobeNewswire JUN 24, 2025 8:00 PM EDTSAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (...READ ARTICLECidara Announces Proposed Public Offering of Common Stock
GlobeNewswire JUN 23, 2025 4:15 PM EDTSAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (...READ ARTICLECidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza
GlobeNewswire JUN 23, 2025 7:00 AM EDTThe study met its primary and all secondary efficacy endpoints for all dose groups Single...READ ARTICLECidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025
GlobeNewswire MAY 15, 2025 8:00 AM EDTSAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company...READ ARTICLECidara Therapeutics to Participate in Two Upcoming Investor Conferences
GlobeNewswire MAY 13, 2025 8:00 AM EDTSAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechno...READ ARTICLECidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
GlobeNewswire MAY 8, 2025 4:15 PM EDTData cutoff date for Phase 2b NAVIGATE trial efficacy reached on April 30, 2025; top-line data re...READ ARTICLE